Welcome to our dedicated page for ImmunityBio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. is reported to be majority-controlled by Patrick Soon-Shiong and affiliated entities. They beneficially own 745,518,285 shares of common stock, representing 64.8% of the class, based on the issuer’s share counts as of July 31, 2026.
Key reporting entities include Cambridge Equities, LP with 261,705,814 shares (24.7%), Nant Capital, LLC with 339,465,528 shares (29.6%), California Capital Equity, LLC with 106,511,412 shares (10.0%), and NantWorks, LLC with 98,535,253 shares (9.3%). Several entities and Dr. Soon-Shiong also hold rights to acquire additional shares within 60 days through stock options and a convertible promissory note, and the structure involves multiple wholly owned and majority-owned subsidiaries through which voting and dispositive power is shared.
ImmunityBio, Inc. reported record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially, marking its eighth consecutive quarter of sequential growth since the commercial launch of ANKTIVA. First-half 2026 net product revenue reached $94.8 million, up 121% versus the first half of 2025. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $357.4 million.
GAAP net loss attributable to common stockholders was $230.4 million in Q2 2026 and $863.2 million for the first half, mainly driven by non-cash changes in the fair value of warrant and derivative liabilities and a related-party convertible note, as well as higher R&D, SG&A and revenue-interest-related interest expense. Adjusted net loss improved to $81.0 million in Q2 2026 and $167.3 million for the first half. Operationally, ImmunityBio reported broader ANKTIVA access, including marketing authorization in the United Arab Emirates, FDA acceptance of an sBLA with a PDUFA target action date of January 6, 2027, and an exclusive U.S. supply agreement for Tokyo-172 BCG.
ImmunityBio, Inc. reports that the Emirates Drug Establishment in the United Arab Emirates has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (including carcinoma in situ and papillary-only disease) and metastatic non-small cell lung cancer after progression on checkpoint inhibitor–based therapy.
The bladder cancer authorization, described as the first worldwide to span the full spectrum of BCG-unresponsive disease, is supported by QUILT-3.032, where ANKTIVA plus BCG produced a 71% complete response rate in the CIS cohort (N=100) and a 12-month disease-free survival rate of 58.2% in papillary-only patients (N=80); Grade 3 treatment-related adverse events occurred in 1% of patients, with no Grade 4 or 5 events reported. The lung cancer indication is backed by QUILT-3.055, showing median overall survival of 14.6 months in checkpoint-refractory advanced NSCLC (N=79) and 16.2 months in patients achieving higher absolute lymphocyte counts. With this decision, ANKTIVA is now authorized in 34 countries, including the UAE, United States, United Kingdom, Saudi Arabia and the European Union.
ImmunityBio, Inc. director Cheryl Cohen reported an exercise-and-sale transaction involving the company’s common stock. On 2026-07-02, she sold 131,210 shares in an open‑market transaction at a weighted average price of $9.5034 per share, under a pre‑arranged Rule 10b5-1 trading plan.
On the same date, Cohen exercised stock options to acquire 55,979 common shares at an exercise price of $2.98 per share, reducing her option position while increasing her direct shareholdings before the sale. Following these transactions, she directly holds 125,386 common shares and 111,958 stock options.
ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares. She exercised options covering 124,414 shares at $2.99 per share and 35,064 shares at $2.98 per share, then sold 159,478 shares of Common Stock in open-market transactions at a weighted average price of $9.0236 per share, within a range of $9.00 to $9.07. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. After these transactions, the filing shows she holds no remaining common shares or related options.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice to sell common stock listed on NASDAQ. The filing lists an intended sale tied to an exercise of stock options for 55,979 shares dated 07/02/2026 and an entry for 75,231 restricted stock units dated 06/06/2021.
ImmunityBio, Inc. director Christobel Selecky exercised stock options and sold the resulting shares in pre-planned trades. On June 29–30, 2026, she exercised options for a total of 96,722 shares of Common Stock at exercise prices between $2.84 and $2.99 per share and sold 96,722 shares in open-market transactions, including 95,722 shares at a weighted-average price of $9.0075 and 1,000 shares at $9.00 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were pre-scheduled rather than discretionary. Following these transactions, Selecky reported no directly held Common Stock, while retaining stock options to purchase additional shares at the disclosed exercise prices and expiration dates.
The issuer reports a proposed resale of 159,478 common shares related to an exercise of stock options to be settled for cash on 07/01/2026. The filing also records recent 10b5-1 sales of 95,722 shares and 1,000 shares on 06/29/2026 and 06/30/2026, respectively, with proceeds shown.
Issuer submitted a Form 144 disclosing a proposed sale and recent transactions in Common Stock.
The filing shows an exercise of 1,000 shares settled for cash on 06/30/2026, and prior 10b5-1 sales by Christobel Selecky of 95,722 shares on 06/29/2026 for $862,212.63.